|
Elan Corporation PLC - Comparative Business Analysis Snapshot
Business Description
Elan Corporation PLC. The Group's principal activity is discovering, developing, manufacturing and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. The Group's operations are carried out through two divisions. Elan Drug Technologies focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Biopharmaceuticals relates to the research, development and commercial activities in the areas of autoimmune diseases, neurodegenerative diseases and specialty business. The Group's product brands are Azactam, Maxipime, MXDAS, NanoCrystal, Naprelan, Prialt, SODAS, Tysabri and Verelan.
Competitor Analysis
This analysis compares Elan Corporation PLC with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
